Patents by Inventor Mark E. Flanagan

Mark E. Flanagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6956041
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: October 18, 2005
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo [2,3-D] pyrimidine compounds
    Patent number: 6890929
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: May 10, 2005
    Assignee: Pfizer, Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Chiral salt resolution
    Publication number: 20040229923
    Abstract: A method for resolving enantiomers of a compound containing the structure of the formula: 1
    Type: Application
    Filed: June 16, 2004
    Publication date: November 18, 2004
    Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20040058922
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: March 25, 2004
    Applicant: Pfizer inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-D]pyrimidine compounds
    Publication number: 20040053947
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: March 18, 2004
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6696567
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20030220353
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 16, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo [2,3-D] pyrimidine compounds
    Publication number: 20030212273
    Abstract: A compound of the formula 1
    Type: Application
    Filed: May 20, 2003
    Publication date: November 13, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
    Patent number: 6635762
    Abstract: Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: October 21, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6627754
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: September 30, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6610847
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Novel crystalline compound
    Publication number: 20030130292
    Abstract: This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.
    Type: Application
    Filed: December 4, 2002
    Publication date: July 10, 2003
    Applicant: Pfizer Inc.
    Inventors: Mark E. Flanagan, Zheng J. Li
  • Chiral salt resolution
    Publication number: 20030073719
    Abstract: A method for resolving enantiomers of a compound containing the structure of the formula: 1
    Type: Application
    Filed: May 23, 2002
    Publication date: April 17, 2003
    Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020068746
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 25, 2001
    Publication date: June 6, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020019526
    Abstract: A compound of the formula 1
    Type: Application
    Filed: September 19, 2001
    Publication date: February 14, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20010053782
    Abstract: A compound of the formula 1
    Type: Application
    Filed: December 8, 2000
    Publication date: December 20, 2001
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • S-alkylthiopropionic acids and derivatives
    Patent number: 5198486
    Abstract: 3-alkylthiopropionic acids are provided which are a direct addition reaction product of an alkylmercaptan and acrylic acid or an alkali metal salt thereof, the reaction being carried out by heating the reactants in the presence of an aqueous alkaline solution having a pH of at least about 11. The acids can be esterified with pentaerythritol in order to form tetraesters which are especially useful as stabilizers for polymer resins and polymers.
    Type: Grant
    Filed: October 1, 1991
    Date of Patent: March 30, 1993
    Assignee: Witco Corporation
    Inventors: Daniel R. Chisolm, Michael H. Fisch, Mark E. Flanagan, Richard D. Peveler
  • 3-alkylthiopropionic acids and derivatives
    Patent number: 5057622
    Abstract: 3-alkylthiopropionic acids are provided which are a direct addition reaction product of an alkylmercaptan and acrylic acid of an alkali metal salt thereof, the reaction being carried out by heating the reactants in the presence of an aqueous alkaline solution having a pH of at least about 11. The acids can be esterified with pentaerythritol in order to form tetraesters which are especially useful as stabilizers for polymer resins and polymers.
    Type: Grant
    Filed: December 10, 1990
    Date of Patent: October 15, 1991
    Assignee: Witco Corporation
    Inventors: Daniel R. Chisholm, Michael H. Fisch, Mark E. Flanagan, Richard D. Peveler
  • Alkylthiopropionic pentaerythritol esters and solvent refining thereof
    Patent number: 5055606
    Abstract: 3-alkylthiopropionic acids which are esterified with pentaerythritol are provided. The esters are solvent refined with especially effective organic solvent blends. Tetraesters thus processed are especially useful as stabilizers for polymer resins and polymers.
    Type: Grant
    Filed: September 25, 1990
    Date of Patent: October 8, 1991
    Assignee: Witco Corporation
    Inventors: Michael H. Fisch, Mark E. Flanagan, Richard D. Peveler